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The Women’s Health Initiative investigators
justifiably concluded that the risk benefit profile
of hormone therapy (HT) is ‘not consistent with
the requirements for a viable intervention for
primary prevention of chronic diseases’.1 This
contradicts the previously widely held belief
that HT was good for older women.2
For many of us this has been quite an
abrupt change in practice, performed often in
front of the patient. This change has required
a shakedown of our health beliefs and the
‘explanatory models’3 we work from.
Examining the reasons behind out attitudes
to HT can help us understand how we can
reach incorrect conclusions. 
Decision making shortcuts
In 1994, the partners in our practice debated
whether to set our computers to prompt us to
consider HT for all women over 50 years of
age who were taking heart disease medication.
We couldn’t agree, and so didn’t implement
the idea, but at the time thought the evidence
was compelling enough to consider doing it. 
How do we assess competing claims? 
The answer is that we use ‘heuristics’ (deci-
sion making shortcuts).4,5 As experts in the
field of general practice we perform much of
our work using shortcuts such as ‘newer is
better’ and ‘experts know best’.6 In most
cases, these shortcuts make it easier for us to
get to the right answer more quickly – but
they can mislead. Newer drugs are not always
better.7 The expertise we rely on may come
from specialist practice and be based mainly
on severe cases that are rare in general prac-
tice. Consequently we need to treat the
shortcuts we use with healthy scepticism and
guard ourselves against being misled.8
How did we come to believe long term HT
was beneficial? 
The evidence indicating that HT was cardio-
protective was only ever observational.9
Observational evidence is more vulnerable to
biases than randomised controlled trial (RCT)
evidence. However, many of us are influ-
enced by the shortcut that if a therapy is
associated with benefits in an observational
study, the therapy must be the cause of that
benefit. We need to remember the ‘healthy
user’ bias in which the positive outcomes in
users of a medication are not due to the
medication but due to the intrinsic health of
the people who seek out and continue taking
the medication.10,11
One of the trickier aspects of our training
is the strong belief in biological causation.
This can lead us to using the shortcut that if
there is a biological theory explaining a phe-
nomenon, it is l ikely to be true.
Consequently, the positive effects of oestro-
gen on lipids reinforced the belief that HT
was cardioprotective.12 This was seen as con-
vincing evidence despite the well known
prothrombotic effect of oestrogen.
Another aspect of medical beliefs that can
lead us astray is that much of our most con-
crete knowledge is based on pathology.
Health promotion is increasingly being
absorbed as part of medicine now that many
of the earlier diseases have faded in impor-
tance in the western world; but most of us
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have trained in a disease based curriculum.
Consequently, we find it much easier to
understand the goals of treatment if we
define a condition as a disease. This makes it
very appealing to use the shortcut that if it is
a variation it must be a disease. Examples of
this include: ‘osteoporosis’, which is an arbi-
trary cut-off point in bone mineral density
rather than a clinical entity, and recently the
‘disease’ of ‘female sexual dysfunction’, a
polyglot collection of intermittent variations
of normal sexual experience now defined as
a disease.13
The shortcut that leads us to often define
variation as disease sets us up for another
shortcut: if it is a disease then we should
treat it. In general practice this usually means
with medication. The whole logic of
menopause being defined as the beginning
of the diseased state of oestrogen deficiency
is exemplified by the popular name of the
treatment ‘hormone replacement therapy’
rather than simply ‘hormone therapy’. Even
the term ‘therapy’ has the implication of
benefit from treating a disease.
As mentioned above, one of the shortcuts
that many of us rely on is to trust experts to
synthesise and report on emerging evidence.
In the 1990s many experts promoted long
term postmenopausal HT as cardioprotective.
We need to think about how these ‘key
opinion leaders’ emerged. The potential
market for the drug companies was huge if
doctors could be convinced that all women
over 50 years of age should take HT for the
rest of their lives. Educators who believed in
the preventive role of HT were well sup-
ported by the pharmaceutical companies and
their talks were therefore more likely to reach
a wide audience. Educators who were more
cautious about HT were less well funded and
thus had less impact. We will no doubt con-
tinue to rely on expert opinion to assist us
translate emerging evidence into clinical prac-
tice. Expert opinion is valuable when the
experts are unbiased and their expertise is
relevant to our practice. 
What is menopause?
Physiologically, menopause is the cessation
of the monthly cycle of ovulation and menstru-
ation in a healthy woman. There is a wide
range of understandings of what menopause
is, including: entering the ‘third age’ for
women,14 a physiological change equivalent to
puberty, an oestrogen deficiency state, and an
oestrogen deficiency disease.
The evidence from RCT moves us away
from considering menopause as an oestro-
gen deficiency disease. If we consider
menopause as a normal life stage change
similar to puberty, how does that alter our
approach in general practice? 
Social ly there is no template for
menopause to be accepted in the way
puberty is accepted. The way we treat
teenagers is worth considering as a model:
we accept them as moody, intolerant, spotty
individuals who blush every time we speak to
them, never tidy their rooms, and go to sleep
at 2 am to rise at 2 pm, hungry. This compari-
son can often help women understand the
demands of their body, their tiredness, their
sadness and their sagginess. Such under-
standing can help them plan constructive
responses. 
It is helpful to reassure women that they will
recover function once their menopausal symp-
toms have resolved. Explaining that there is no
correlation between life satisfaction and
menopausal status15 can help them focus on
the issues that really influence their satisfaction. 
Conclusion
Clearly we cannot put every shortcut under
the microscope; however, where there has
been a major revision of practice such as in
the change of medical attitudes to
menopause, understanding how our practice
was shaped can help us to respond better
and identify the goals of treatment more
clearly. Although shortcuts are necessary for
efficient practice and usually help us, we
need to remain alert to the biases such as
our own health beliefs (pathology based) and
marketing biases (pharmaceutical company
sponsorship). Reflective practice when
assessing new evidence or new tools (eg.
drugs, equipment) can help us to understand
and critique the influences on our day-to-day
practice. Being conscious of the shortcuts
we use will enable better general practice.
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